Japara Healthcare Limited, together with its subsidiaries, owns, develops, and operates residential aged care homes in Australia. More Details
Reasonable growth potential and fair value.
Share Price & News
How has Japara Healthcare's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: JHC's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: JHC underperformed the Australian Healthcare industry which returned 3.9% over the past year.
Return vs Market: JHC underperformed the Australian Market which returned -6.9% over the past year.
Price Volatility Vs. Market
How volatile is Japara Healthcare's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StJapara Healthcare (ASX:JHC) Has No Shortage Of Debt
2 months ago | Simply Wall StHave Insiders Been Buying Japara Healthcare Limited (ASX:JHC) Shares?
3 months ago | Simply Wall StIs It Too Late To Consider Buying Japara Healthcare Limited (ASX:JHC)?
Is Japara Healthcare undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: JHC (A$0.4) is trading below our estimate of fair value (A$3.55)
Significantly Below Fair Value: JHC is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: JHC is unprofitable, so we can't compare its PE Ratio to the AU Healthcare industry average.
PE vs Market: JHC is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate JHC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: JHC is good value based on its PB Ratio (0.5x) compared to the AU Healthcare industry average (1.5x).
How is Japara Healthcare forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: JHC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: JHC is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: JHC's is expected to become profitable in the next 3 years.
Revenue vs Market: JHC's revenue (6% per year) is forecast to grow faster than the Australian market (4.6% per year).
High Growth Revenue: JHC's revenue (6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: JHC's Return on Equity is forecast to be low in 3 years time (2.2%).
How has Japara Healthcare performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: JHC is currently unprofitable.
Growing Profit Margin: JHC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: JHC is unprofitable, and losses have increased over the past 5 years at a rate of 62.2% per year.
Accelerating Growth: Unable to compare JHC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: JHC is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-8.1%).
Return on Equity
High ROE: JHC has a negative Return on Equity (-131%), as it is currently unprofitable.
How is Japara Healthcare's financial position?
Financial Position Analysis
Short Term Liabilities: JHC's short term assets (A$71.4M) do not cover its short term liabilities (A$747.2M).
Long Term Liabilities: JHC's short term assets (A$71.4M) do not cover its long term liabilities (A$281.9M).
Debt to Equity History and Analysis
Debt Level: JHC's debt to equity ratio (109.5%) is considered high.
Reducing Debt: JHC's debt to equity ratio has increased from 0.2% to 109.5% over the past 5 years.
Debt Coverage: JHC's debt is well covered by operating cash flow (30.8%).
Interest Coverage: JHC is unprofitable, therefore interest payments are not well covered by earnings.
What is Japara Healthcare current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate JHC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate JHC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if JHC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if JHC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: JHC is not paying a notable dividend for the Australian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of JHC's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Chris Price (55 yo)
Mr. Christopher Murray Price, also known as Chris, B. Bus, CA, serves as Secretary at Japara Holdings Pty Ltd. Mr. Price had been the Chief Financial Officer of Japara Healthcare Limited since June 22, 201 ...
CEO Compensation Analysis
Compensation vs Market: Chris's total compensation ($USD519.17K) is above average for companies of similar size in the Australian market ($USD277.63K).
Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.
|CEO, MD & Director||0.58yr||AU$730.00k||0.049% |
|CFO & Chief Investment Officer||0.58yr||AU$550.82k||no data|
|Chief Operations Officer||0.67yr||AU$371.34k||no data|
|Group Executive of Information Communications & Technology||0.33yr||no data||no data|
|Chief HR Officer||1.75yrs||no data||no data|
|Group Executive of Senior Living||0.33yr||no data||no data|
|Chief Clinical Governance & Risk Officer||0.75yr||no data||no data|
|Company Secretary||4.83yrs||no data||no data|
Experienced Management: JHC's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.
|CEO, MD & Director||0.58yr||AU$730.00k||0.049% |
|Independent Non Executive Director||6.58yrs||AU$105.00k||0.034% |
|Non-Executive Chairman||no data||AU$250.00k||0.091% |
|Independent Non-Executive Director||1.25yrs||AU$125.00k||0.043% |
|Independent Non-Executive Director||5.08yrs||AU$125.00k||0.023% |
Experienced Board: JHC's board of directors are considered experienced (3.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Japara Healthcare Limited's company bio, employee growth, exchange listings and data sources
- Name: Japara Healthcare Limited
- Ticker: JHC
- Exchange: ASX
- Founded: 2005
- Industry: Health Care Facilities
- Sector: Healthcare
- Market Cap: AU$106.758m
- Shares outstanding: 266.89m
- Website: https://japara.com.au
Number of Employees
- Japara Healthcare Limited
- Q1 Building
- Level 4
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|JHC||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Apr 2014|
|JHC||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Apr 2014|
|7JH||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Apr 2014|
Japara Healthcare Limited, together with its subsidiaries, owns, develops, and operates residential aged care homes in Australia. It operates approximately 4,400 resident places across 51 homes located in ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/25 10:38|
|End of Day Share Price||2020/10/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.